As advised in early July 2025, the National Blood Authority (NBA) finalised a procurement for new national contracts for standard half-life (SHL) and extended half-life (EHL) recombinant Factor VIII (rFVIII) and recombinant Factor IX (rFIX) for the treatment of haemophilia A and B. These new supply arrangements took effect from 1 July 2025.
As an outcome of this procurement process, all products provided under the previous supply arrangements continue to be available with the exception of SHL rFVIII Advate, manufactured by Takeda Pharmaceuticals Australia Pty Ltd (Takeda). In addition to the previously supplied products, EHL rFIX product Idelvion has become available under the new arrangements.
A 10 month transition period has been determined for Advate in consultation with Takeda, from the conclusion of the previous supply arrangement on 30 June 2025. As a result, Advate will remain available to clinicians and patients until the end of April 2026.
The NBA will be distributing transition materials directly to stakeholders to ensure that the sector is prepared for this transition.
